ACAD
31.23
+0.18
+0.58%
AEMD
0.25
0.00
-0.83%
APRI
1.42
-0.01
-0.70%
ARNA
4.42
-0.09
-2.00%
ATEC
1.28
-0.03
-2.29%
CFN
59.42
-0.18
-0.30%
CNAT
5.91
-0.05
-0.84%
CRXM
0.17
-0.04
-18.96%
CYTX
0.48
+0.01
+1.23%
DXCM
60.82
-0.18
-0.30%
GNMK
13.11
-0.2
-1.50%
HALO
14.55
-0.04
-0.27%
ILMN
199.28
-0.72
-0.36%
INNV
0.22
+0.01
+4.19%
INO
8.41
-0.09
-1.11%
ISCO
0.06
0.00
-3.23%
ISIS
69.79
-0.07
-0.10%
LGND
56.28
-0.75
-1.32%
LPTN
2.82
-0.03
-1.05%
MBVX
1.03
-0.02
-1.90%
MEIP
3.93
+0.07
+1.89%
MNOV
3.75
-0.02
-0.56%
MRTX
21
-0.29
-1.36%
MSTX
0.45
+0.02
+4.48%
NBIX
34.49
+0.14
+0.41%
NUVA
46.75
-0.55
-1.16%
ONCS
0.36
-0.01
-1.42%
ONVO
6.57
-0.12
-1.79%
OREX
5.37
+0.02
+0.37%
OTIC
30.56
-1.01
-3.20%
QDEL
23.72
-0.75
-3.06%
RCPT
114.18
+1.47
+1.30%
RGLS
19.07
+0.49
+2.64%
RMD
62.86
-0.17
-0.27%
SCIE
0.01
+0.00
+1.77%
SPHS
0.47
0.00
-0.15%
SRNE
10.47
-0.32
-2.92%
TROV
6.39
+0.56
+9.61%
VICL
1.04
0.00
0.00%
VOLC
17.97
+0.01
+0.06%
ZGNX
1.39
+0.02
+1.09%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.